Company Filing History:
Years Active: 2017
Title: Anna Linsenmeier: Innovator in Pharmaceutical Modulation
Introduction
Anna Linsenmeier is a notable inventor based in Ludwigshafen, Germany. She has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that modulate serotonin receptors. With a total of 2 patents, her work is pivotal in addressing various medical conditions.
Latest Patents
Linsenmeier's latest patents include innovative compounds such as substituted [1,4]diazepino[6,7,1-ij]quinolines, which serve as serotonin 5-HT2C receptor modulators. This invention relates to a compound of formula (I) that is useful for modulating the 5-HT receptor, thereby preventing and treating conditions that respond to this modulation. Additionally, she has developed hexahydrodiazepinoquinolines carrying a substituted alkyl radical, which are also aimed at modulating the 5-HT receptor. These compounds are essential for preparing medicaments for various disorders.
Career Highlights
Throughout her career, Anna Linsenmeier has worked with prominent companies such as AbbVie Deutschland GmbH and Co. KG. Her experience in these organizations has allowed her to refine her expertise in pharmaceutical development and innovation.
Collaborations
Linsenmeier has collaborated with notable colleagues, including Gisela Backfisch and Margaretha Henrica Maria Bakker. These partnerships have contributed to her success in the field and have fostered a collaborative environment for innovation.
Conclusion
Anna Linsenmeier's contributions to pharmaceutical sciences through her patents and collaborations highlight her role as a significant innovator. Her work continues to impact the development of treatments for various medical conditions.